ÂÜÀòÂÒÂ×

As Co-Founder, Dr. Chander developed Cellanyx’s live cell phenotypic technology. He served as founding CEO until Feb. 2019. . Dr. Chander previously conducted academic research in multidrug resistance, distributed networks, and matrix-biology. Dr. Chander combines his background in biophysics with engineering project management, and phenotypic laboratory developed tests (LDT) development. Dr. Chander received his S.B. in Biology from MIT and a Ph.D. from Columbia University.